<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117808">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02077569</url>
  </required_header>
  <id_info>
    <org_study_id>12076</org_study_id>
    <nct_id>NCT02077569</nct_id>
  </id_info>
  <brief_title>AKT Inhibitor in Oestrogen Positive Breast Cancer</brief_title>
  <acronym>STAKT</acronym>
  <official_title>The Short Term Effects of an AKT Inhibitor (AZD5363) on Biomarkers of the AKT Pathway and Anti-tumour Activity in a Breast Cancer Paired Biopsy Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nottingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Trials Awards and Advisory Committee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Nottingham</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effect of four and a half days treatment of a range of doses of AZD5363 on
      selected markers of the AKT pathway and anti-proliferation compared with placebo in
      oestrogen receptor positive breast cancers.

      To assess the tolerability of four and a half days treatment of AZD5363.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The principal research questions to be addressed are whether (or not) AZD5363 is &quot;hitting
      its therapeutic target&quot; sufficiently and to the extent that is required to produce efficacy
      in pre-clinical experiments.

      The primary endpoint markers have been selected to determine this.

      Reductions in markers of the AKT pathway and increases in markers of anti-proliferation will
      characterise the degree of biological activity arising from the inhibition of AKT across a
      range of doses of AZD5363.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Health Services Research</study_design>
  <primary_outcome>
    <measure>Primary endpoint: Pharmacodynamic biomarker analysis in tumour tissue to assess the biological effect of AZD5363 on markers of anti-proliferation and the AKT pathway</measure>
    <time_frame>Up to 30 months: Stage 1 - 60 participants, up to 12 months.  Stage 1 biomarker analysis early in Stage 2.  Stage 2 proceeds where reduction in 1 of the  3 primary biomarkers.  Stage 2 - up to 90 participants, up to 16 months.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Changes in pPRAS40, pGSK3b, Ki67</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare anti-proliferative effect on markers of the AKT pathway after 4&amp;1/2days treatment at 3 different doses of AZD5363 vs placebo in Er +ve breast cancers</measure>
    <time_frame>Up to 30 months. Stage 1: 60 participants in up to12 months.  Stage 2: 90 participants in up to 26 months.</time_frame>
    <safety_issue>No</safety_issue>
    <description>By measuring biological changes in the tumour and circulation via measurement of changes in alternative biological markers which relate to the AKT pathway:
Tumour total and pAKT Tumour: cleaved caspase 3; pS6 (IHC); FOXO3a Blood (platelet-rich plasma): Total and pPRAS40; Total and pGSK3b; Total and pAKT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare direct effect on markers of the AKT pathway after 4&amp;1/2days treatment at 3 different doses of AZD5363 vs placebo in Er +ve breast cancers</measure>
    <time_frame>Up to 30 months. Stage 1: 60 participants in  up to12 months.  Stage 2: 90 participants in up to 26 months.</time_frame>
    <safety_issue>No</safety_issue>
    <description>By measuring biological changes in the tumour and circulation via measurement of changes in alternative biological markers which relate to the AKT pathway:
Tumour total and pAKT Tumour: cleaved caspase 3; pS6 (IHC); FOXO3a Blood (platelet-rich plasma): Total and pPRAS40; Total and pGSK3b; Total and pAKT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To measure tolerability and toxicity following short term (four and a half days) exposure to AZD5363</measure>
    <time_frame>Up to 30 months. Stage 1: 60 participants in up to12 months.  Stage 2: 90 participants in up to 26 months.</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Tolerability and toxicity will be measured following short term exposure to AZD5363 by incidence and severity of adverse events.
Participants will be monitored for adverse events during the study and for at least 30 days after the end of treatment.
Analysis of toxicity following the completion of Stage 1,  taking into consideration that Stage 2 will use lower doses of AZD5363, and at the end of Stage 2.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Invasive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>AZD5363 480mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD5363 480mg Twice daily dosing for 4 and 1/2 days (9 doses) Oral Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Twice daily dosing for 4 and 1/2 days (9 doses) Oral Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD360mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD5363  360mg Twice daily dosing for 4 and 1/2 days (9 doses) Oral Capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD5363 240mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AZD5363 240mg Twice daily dosing for 4 and 1/2 days (9 doses) Oral Capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD5363</intervention_name>
    <description>Stage 1: AZD5363 480mg or placebo twice daily oral dosing for 4 and 1/2 days (9 doses) Stage 2: AZD5363 360mg or 240mg or placebo twice daily oral dosing for 4 and 1/2 days (9 doses)</description>
    <arm_group_label>AZD5363 480mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>AZD360mg</arm_group_label>
    <arm_group_label>AZD5363 240mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        WHO performance status 0-1 with no deterioration over the previous 2 weeks. Able to
        swallow &amp; retain oral medication. Post-menopausal. Female patients with histological
        confirmation of ER positive invasive breast carcinoma.

        Stage 1/2/3 or Stage 4 with primary tumour in the breast amenable to biopsies. Scheduled
        to have chemotherapy (with or without surgery) based on tumour characteristics and local
        treatment protocols.

        Tumours large enough to provide sufficient tissue to be taken by core-cut or tru-cut
        biopsy (free-hand or under ultrasound guidance as per local protocols) to provide tissue
        sections for the marker assays.

        -

        Exclusion Criteria:

        Any one of the following will exclude a patient from entering the trial:

        Prior treatment for breast cancer. Treatment with HRT within 4 weeks prior to trial
        treatment. Known ER negative tumour. Female patients with histological confirmation of ER
        positive invasive breast carcinoma not scheduled to have chemotherapy (with or without
        surgery) based on tumour characteristics and local treatment protocols.

        Exposure to potent inhibitors or inducers of CYP3A4 or CYP2D6 or substrates of CYP3A4
        within 2 weeks before the first dose of study treatment (3 weeks for St Johns Wort).

        Clinically significant abnormalities of glucose metabolism as defined by any of the
        following:    Diagnosis of diabetes mellitus type I or II;    Glycosylated haemoglobin
        (HbA1C) &gt;64 mmol/mol/8.0% at screening;    Fasting Plasma Glucose &gt;7.0mmol/L at screening.

        Major surgery (excluding placement of vascular access) within 4 weeks before the first
        dose of study treatment.

        Spinal cord compression or brain metastases. Evidence of severe or uncontrolled systemic
        disease.

        Any of the following cardiac criteria:

        Mean resting corrected QT interval (QTc)&gt;450 msec obtained from 3 consecutive ECGs;    Any
        clinically important abnormalities in rhythm, conduction or morphology of resting ECG;
        Any factors that increase the risk of QTc prolongation or risk of arrhythmic events.

        Any of the following procedures or conditions in the preceding 6 months: coronary artery
        bypass graft, angioplasty, vascular stent, myocardial infarction, angina pectoris,
        congestive heart failure NYHA Grade 2.

        Uncontrolled hypotension - SBP &lt;90 mmHg and/or DBP &lt;50 mmHg. Absolute neutrophil count
        &lt;1.5 x 10 /L. Platelet count &lt;100 x 19 /L. Haemoglobin &lt;90 g/L (&lt;9g/dL / &lt;5.59 mmol/L).
        Alanine aminotransferase (ALT) &gt;2.5 times ULN if no demonstrable liver metastases or &gt;5
        times ULN in the presence of liver metastases.

        Elevated Alkaline phosphatase (ALP) is not exclusionary if due to the presence of bone
        metastasis and liver function is otherwise considered adequate in the investigator's
        judgement.

        Total bilirubin &gt;1.5 times ULN if no liver metastases or &gt;3 times ULN in the presence of
        liver metastases.

        Creatinine &gt;1.5 times ULN concurrent with creatinine clearance &lt;50 ml/min; confirmation of
        creatinine clearance is only required when creatinine is &gt;1.5 times ULN Proteinuria &gt;3+ on
        dipstick analysis. Refractory nausea and vomiting, chronic gastrointestinal diseases,
        inability to swallow the formulated product or previous significant bowel resection that
        would preclude adequate absorption of AZD5363.

        History of hypersensitivity to active or inactive excipients of AZD5363 or drugs with a
        similar chemical structure or class to AZD5363.

        Current disease or condition known to interfere with absorption, distribution, metabolism
        or excretion of drugs.

        Past medical history of interstitial lung disease, drug induced interstitial lung disease,
        radiation pneumonitis which required steroid treatment, or any evidence of clinically
        active interstitial lung disease.

        Evidence of dementia, altered mental status or any psychiatric condition that would
        prohibit understanding or rendering of informed consent Previous allogeneic bone marrow
        transplant. Immunodeficiency syndrome.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John FR Robertson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Nottingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John FR Robertson, MD</last_name>
    <phone>0044 1332724881</phone>
    <email>john.robertson@nottingham.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Royal Derby Hospital</name>
      <address>
        <city>Derby</city>
        <state>Derbyshire</state>
        <zip>DE22 3DT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KL Cheung, MB</last_name>
      <phone>0044 1332724881</phone>
      <email>kl.cheung@nottingham.ac.uk</email>
    </contact>
    <investigator>
      <last_name>KL Cheung, MB</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John FR Robertson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Bournemouth Hospital</name>
      <address>
        <city>Bournemouth</city>
        <state>Dorset</state>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Skene, MS FRCS</last_name>
      <phone>0044 1202303626</phone>
      <email>anthony.skene@rbch.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Anthony Skene, MS FRCS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Poole Hospital NHS Foundation Trust</name>
      <address>
        <city>Poole</city>
        <state>Dorset</state>
        <zip>BH15 2JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abigail Evans, MD</last_name>
      <phone>0044 1202442616</phone>
      <email>abigail.evans@poole.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Abigail Evans, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <state>Leicestershire</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samreen Ahmed, MD</last_name>
      <phone>0044 1162586295</phone>
      <email>samreen.ahmed@uhl-tr.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Samreen Ahmed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Grantham District Hospital</name>
      <address>
        <city>Grantham</city>
        <state>Linconshire</state>
        <zip>NG31 8DG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anupam M Modi, MD</last_name>
      <phone>01522 512512</phone>
      <phone_ext>3259</phone_ext>
      <email>anupam.modi@ulh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Anupam K Modi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <state>Lothian</state>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mike Dixon, MD</last_name>
      <phone>0044 1315372643</phone>
      <email>mike.dixon@ed.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Mike Dixon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oliver Young, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool University Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>Merseyside</state>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Holcombe, MD</last_name>
      <phone>0044 1517063459</phone>
      <email>chris.holcombe@rlbuht.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Chris Holcombe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kingsmill Hospital</name>
      <address>
        <city>Sutton-in-Ashfield</city>
        <state>Nottinghamshire</state>
        <zip>NG17 4JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mohamed A Jahan, MD</last_name>
      <phone>01623 622 515</phone>
      <phone_ext>3960</phone_ext>
      <email>Mohamed.jahan@sfh-tr.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Mohamed A Jahan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheffield Cancer Research Centre</name>
      <address>
        <city>Sheffield</city>
        <state>South Yorkshire</state>
        <zip>S10 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rob Coleman</last_name>
      <phone>0044 1142265213</phone>
      <email>r.e.coleman@sheffiled.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Rob Coleman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ninewells Hopsital &amp; Medical School</name>
      <address>
        <city>Dundee</city>
        <state>Tayside</state>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane E MacAskill, MD</last_name>
      <phone>0044 1382632565</phone>
      <email>ejanemacaskill@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Alastair M Thompson, MD</last_name>
      <phone>0044 1382632565</phone>
      <email>a.m.thompson@dundee.ac.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Jane E MacAskill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alastair M Thompson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Birmingahm</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B15 2TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Rae, MD</last_name>
      <phone>0120 2303626</phone>
      <email>d.w.rea@bham.ac.uk</email>
    </contact>
    <contact_backup>
      <last_name>Adele Francis, MD</last_name>
      <phone>01213715036</phone>
      <email>adele.francis@ehb.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Rea, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adele Francis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leeds St James Institue of Oncology</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keiran Horgan, MD</last_name>
      <phone>0113 243 2799</phone>
      <email>kieran.horgan@leedsth.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Keiran Horgan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 8, 2014</lastchanged_date>
  <firstreceived_date>January 16, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AKT inhibitor</keyword>
  <keyword>AZD5363</keyword>
  <keyword>Anti-tumour activity</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>ER positive</keyword>
  <keyword>Oestrogen positive</keyword>
  <keyword>post menopausal</keyword>
  <keyword>chemotherapy required</keyword>
  <keyword>no prior cancer treatment</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Estrogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
